Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Director Manuel Hidalgo Medina of Guardant Health [GH] received new equity compensation grants on June 18, 2025, consisting of:
- Stock Options: Granted 6,833 options to buy common stock at an exercise price of $50.57, which vest fully on June 18, 2026 or the next annual stockholders meeting, whichever occurs first. The options expire on June 18, 2035.
- Restricted Stock Units (RSUs): Awarded 4,203 RSUs that vest fully on June 18, 2026 or the next annual stockholders meeting, whichever occurs first.
This Form 4 filing, submitted by attorney-in-fact John G. Saia on June 20, 2025, represents standard director compensation equity grants. The combined awards suggest continued board engagement and alignment with shareholder interests through both performance-based options and time-vested RSUs.
Guardant Health director Vijaya Gadde received new equity compensation grants on June 18, 2025, consisting of:
- Stock options to purchase 6,833 shares of common stock at an exercise price of $50.57 per share, expiring June 18, 2035
- 4,203 Restricted Stock Units (RSUs) with no exercise price
Both the stock options and RSUs will fully vest on the earlier of: (1) the one-year anniversary of the grant date (June 18, 2025) or (2) the date of the next annual stockholders meeting. This equity compensation package appears to be part of standard director compensation. The Form 4 was filed by John G. Saia as attorney-in-fact for Vijaya Gadde on June 20, 2025.
Guardant Health Director Ian T. Clark reported multiple securities transactions on June 17-18, 2025:
- Disposed of 6,672 shares of common stock at an average price of $48.38 per share from the Thornton-Clark Family Trust
- Received a new stock option grant for 6,833 shares with exercise price of $50.57, vesting in full on June 18, 2025 or next annual stockholders meeting
- Granted 5,092 restricted stock units (RSUs) vesting in full on June 18, 2025 or next annual stockholders meeting
Following these transactions, Clark retains 9,851 shares indirectly through the family trust, plus the new equity awards. The stock sale was executed in multiple transactions within a $0.03 price range.
Guardant Health, Inc. (GH) filed a Form 144 notice for a planned sale of restricted stock that recently vested. The filing discloses that 3,213 shares of GH common stock are expected to be sold through broker Charles Schwab & Co., Inc. on or about 18 June 2025. The estimated aggregate market value of the proposed sale is $158,947. Compared with the company’s 123,888,045 shares outstanding, the transaction represents roughly 0.0026 % of total shares, indicating a de-minimis impact on the public float.
The seller—identified in the filing as Musa Tariq—acquired the shares on 15 June 2025 via the lapse of restrictions on equity compensation. Over the past three months Mr. Tariq has sold an additional 348 shares of Guardant Health stock across three transactions, generating $14,910 in gross proceeds. No relationship to the issuer is specified in the document, and the form states that the filer is unaware of any non-public material adverse information.
Because Form 144 covers proposed sales under Rule 144 and does not obligate the insider to complete the trade, investors typically view such filings as information events rather than firm commitments. Given the small size of the sale relative to Guardant Health’s market capitalization, the filing is unlikely to exert material pressure on share price but does provide incremental insight into insider trading intentions.